| 李丽萍,李 晶,谭平萍,袁 理,陈 凯,曾 亮.Kallistatin在乳腺癌中表达的临床病理意义[J].现代生物医学进展英文版,2020,(6):1124-1128. |
| Kallistatin在乳腺癌中表达的临床病理意义 |
| Clinicopathological Significance of Kallistatin Expression in Breast Cancer |
| Received:September 23, 2019 Revised:October 19, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.06.028 |
| 中文关键词: 激肽抑制素 乳腺癌 临床病理 |
| 英文关键词: Kallistatin Breast cancer Clinicopathology |
| 基金项目:湖南省卫生计生委科研计划项目（B2017097）；广州市妇女儿童医疗中心内部基金（5001-2170099） |
| Author Name | Affiliation | E-mail | | LI Li-ping | Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510623, China | 18874093428@163.com | | LI Jing | Department of Breast Medicine, Hunan Cancer Hospital, Changsha, Hunan, 410356, China | | | TAN Ping-ping | Department of Pathology, Hunan Cancer Hospital, Changsha, Hunan, 410356, China | | | YUAN Li | Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510623, China | | | CHEN Kai | Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510623, China | | | ZENG Liang | Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, 510623, China | |
|
| Hits: 736 |
| Download times: 490 |
| 中文摘要: |
| 摘要 目的：探讨Kallistatin在乳腺癌中表达的临床病理意义及预后价值。方法：收集乳腺癌档案蜡块及临床资料，分为无淋巴结转移的原发灶(NMBT)，有淋巴结转移的原发灶(PBT)及配对的淋巴结转移灶（PMLN)，应用免疫组化技术检测Kallistatin表达，统计学分析。结果：结果显示kallistatin在PBT组的表达高于NMBT组合和PMLN组。kallistatin的表达与组织学类型（P=0.003）、淋巴结状态（P<0.001）、临床分期（P=0.002）、雌激素受体（ER）表达（P=0.046）有显著相关性。kallistatin在浸润性小叶癌中的阳性表达率高于浸润性导管癌，在PBT组的阳性表达率显著高于NMBT，临床分期越晚期阳性表达率越高，在ER阳性的病历中表达更高。Kaplan-Meier分析显示，kallistatin的阳性表达是乳腺癌患者无病生存时间短（P=0.008）和总生存时间短（P=0.006）的危险因素。在浸润性乳腺导管癌患者中，kallistatin的阳性表达与生存时间短有关（P=0.026）。还与ER阳性表达患者生存时间较短有关（P=0.010）。结论：Kallistatin在乳腺癌中的表达有较为复杂的临床病理意义，其表达提示预后不良。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinicopathological significance and prognostic value of Kallistatin expression in breast cancer. Methods: The wax mass and clinical data of breast cancer archives were collected and divided into primary non-lymph node metastasis (NMBT), primary lymph node metastasis (PBT) and matched lymph node metastasis (PMLN). The expression of Kallistatin was detected by immunohistochemical technique and analyzed statistically. Results: The results showed that the expression of kallistatin in primary lymph node metastasis was higher than that in primary lymph node metastasis without lymph node metastasis and matched lymph node metastasis. The expression of kallistatin was significantly correlated with histological type (P=0.003), lymph node status (P< 0.001), clinical stage (P=0.002), estrogen receptor (ER) expression (P=0.046). The positive expression rate of kallistatin in invasive lobular carcinoma was higher than that in invasive ductal carcinoma. The positive expression rate of kallistatin in breast cancer with lymph node metastasis was significantly higher than that in breast cancer without lymph node metastasis. Kaplan-Meier analysis showed that the positive expression of kallistatin was a risk factor for short disease-free survival (P=0.008) and short overall survival (P=0.006) in breast cancer patients. In patients with invasive ductal breast cancer, the positive expression of kallistatin was associated with short survival time (P=0.026). It was also related to the short survival time of ER positive patients(P=0.010). Conclusion: The expression of Kallistatin in breast cancer has more complicated clinicopathological significance, and its expression suggests poor prognosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
